Cross-talk between the CK2 and AKT signaling pathways in cancer
CK2 and AKT display a high degree of cross-regulation of their respective functions, both
directly, through physical interaction and phosphorylation, and indirectly, through an intense …
directly, through physical interaction and phosphorylation, and indirectly, through an intense …
Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors
The incidence of cancer is increasing worldwide, but the biochemical mechanisms for the
occurrence of cancer is not fully understood, and there is no cure for advanced tumors …
occurrence of cancer is not fully understood, and there is no cure for advanced tumors …
[HTML][HTML] Protein kinase CK2, a potential therapeutic target in carcinoma management
H Lian, M Su, Y Zhu, Y Zhou… - Asian Pacific journal of …, 2019 - ncbi.nlm.nih.gov
The Protein kinase CK2 (formerly known as casein kinase 2) is a highly conserved
serine/threonine kinase overexpressed in various human carcinomas and its high …
serine/threonine kinase overexpressed in various human carcinomas and its high …
[HTML][HTML] Preclinical in vitro and in vivo evidence of an antitumor effect of CX-4945, a casein kinase II inhibitor, in cholangiocarcinoma
K Zakharia, K Miyabe, Y Wang, D Wu, CD Moser… - Translational …, 2019 - Elsevier
PURPOSE: We investigated the antitumor effect of the casein kinase II (CK2) inhibitor CX-
4945 on cholangiocarcinoma (CCA). METHODS: We assessed the effect of CX-4945 alone …
4945 on cholangiocarcinoma (CCA). METHODS: We assessed the effect of CX-4945 alone …
Casein kinase II (CK2) as a therapeutic target for hematological malignancies
C Gowda, M Sachdev, S Muthusami… - Current …, 2017 - ingentaconnect.com
Background: Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a
promising therapeutic target in cancer. Recent studies have revealed an important role for …
promising therapeutic target in cancer. Recent studies have revealed an important role for …
Short-chain L-3-hydroxyacyl-CoA dehydrogenase: A novel vital oncogene or tumor suppressor gene in cancers
H Fang, H Li, H Zhang, S Wang, S Xu… - Frontiers in …, 2022 - frontiersin.org
The reprogramming of cellular metabolism is frequently linked to tumorigenesis. Glucose,
fatty acids, and amino acids are the specific substrates involved in how an organism …
fatty acids, and amino acids are the specific substrates involved in how an organism …
An update on PTEN modulators–a patent review
CS Boosani, P Gunasekar… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: A multitude of cellular and physiological functions have been attributed to the
biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting …
biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting …
Transcriptional regulation of JARID1B/KDM5B histone demethylase by ikaros, histone deacetylase 1 (HDAC1), and casein kinase 2 (CK2) in B-cell acute …
Impaired function of the Ikaros (IKZF1) protein is associated with the development of high-
risk B-cell precursor acute lymphoblastic leukemia (B-ALL). The mechanisms of Ikaros tumor …
risk B-cell precursor acute lymphoblastic leukemia (B-ALL). The mechanisms of Ikaros tumor …
Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update
C Simioni, AM Martelli, G Zauli, M Vitale… - Journal of Cellular …, 2018 - Wiley Online Library
Despite considerable progress in treatment protocols, B‐lineage acute lymphoblastic
leukemia (B‐ALL) displays a poor prognosis in about 15–20% of pediatric cases and about …
leukemia (B‐ALL) displays a poor prognosis in about 15–20% of pediatric cases and about …
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia
High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive disease, often
characterized by resistance to chemotherapy. A frequent feature of high-risk B-ALL is loss of …
characterized by resistance to chemotherapy. A frequent feature of high-risk B-ALL is loss of …